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Abstract 
Antidepressants are psychiatric agents used for the treatment of different types 
of depression being at present amongst the most commonly prescribed drug, 
while their effectiveness and adverse effects are the subject of many studies 
and competing claims. Having studied five QSAR models predicting the 
biological activities of 18 antidepressants, already approved for clinical 
treatment, in interaction with the serotonin transporter (SERT), we attempted to 
establish the membrane ions’ contributions (sodium, potassium, chlorine and 
calcium) supplied by donor/acceptor hydrogen bond character and electrostatic 
field to the antidepressant activity. Significant cross-validated correlation q
2 
(0.5–0.6) and the fitted correlation r
2 (0.7–0.82) coefficients were obtained 
indicating that the models can predict the antidepressant activity of compounds. 
Moreover, considering the contribution of membrane ions (sodium, potassium 
and calcium) and hydrogen bond donor character, we have proposed a library 
of 24 new escitalopram structures, some of them probably with significantly 
improved antidepressant activity in comparison with the parent compound. 
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Introduction 
The World Health Organization reported that depressive disorders, particularly unipolar, 
are one of the leading causes of total disability-adjusted life-years (DALYs) worldwide [1]. 
Major depressive disorders have a number of causes: endothelial dysfunction, genetic risk 
factors, genetically determined personality factors, adverse childhood experiences [2] and 
is characterized, generally, by pervasive low mood, anxiety, inhibition of the cognitive 
process, loss of interest in a person's usual activities and suicidal behaviors [3]. The cost-
effectiveness of more new antidepressant agents is superior to that of tricyclic 
antidepressants or selective serotonin reuptake inhibitors [4, 5]. Some of antidepressant 
agents are as follows [6]: serotonin-reuptake inhibitors – SSRIs, selective norepinephrine-
reuptake inhibitors – NRIs, nonselective norepinephrine-reuptake inhibitors, dual-action 
reuptake inhibitors, monoamine oxidase inhibitors – MAOIs and new agents with complex 
mechanism of action. Recently, the British Association for Psychopharmacology has 
recommended [7] to choose those antidepressants that are better tolerated and safer in 
overdose. Thus, the combination of a SSRI with a newer agent represents the first line-
treatment choice. Beyond their effectiveness in medical management of depression, 
SSRIs are recommended also in other conditions, such as anxiety disorders, panic 
disorders and social phobia [8]. Escitalopram is the newest and most selective of SSRIs 
approved by the FDA for depression treatment [9, 10]. In an Austrian study, six months 
after treatment start, the rate of clinical remission was higher for escitalopram treated 
patients than for citalopram (53.7% vs. 48.7%) and the cost for successfully treated 
patients with severe depression was with 24.4% lower for escitalopram than for citalo-
pram [11]. 
The lack of knowledge regarding the three-dimensional structures of the membrane 
receptors and the high costs of antidepressants synthesis [12] can be real obstacles for 
psycho-pharmaceutical studies. Under these conditions, the quantitative structure-activity 
relationship (QSAR) represents a suitable way to predict the biological activity of new 
antidepressants, in the presence of different biological membrane components. At the 
level of the central nervous system, the influence of membrane ions (sodium, potassium, 
chlorine and calcium) upon drug action is critical. In our intention to augment the 
information about antidepressants’ mechanisms of action, in this paper we will establish by 
using 3D-QSAR the membrane ions’ contributions (sodium, potassium, chlorine and 
calcium) supply by donor/acceptor hydrogen bond and electrostatic field to the 
antidepressant activity of escitalopram, along with other serotonin-reuptake inhibitors 
(zimelidine, fluoxetine, paroxetine, sertraline, fluvoxamine), selective norepinephrine-
reuptake inhibitors (reboxetine and atomoxetine), nonselective norepinephrine-reuptake 
inhibitors (desipramine, nortryptiline), dual-action reuptake inhibitors (amitriptyline, 
imipramine, venlafaxine, milnacipran, duloxetine), new agents with complex mechanism of 
action like mirtazapine, nefazodone and trazodone at the SERT active site. In this study 
we have not chosen a large number of molecules in the training set but other important 
criteria like clinical indication of antidepressants mentioned above, large range of affinity of 
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Also, in our attempt to obtain novel escitalopram derivatives with fewer side-effects and a 
higher affinity to the serotonin transporter, a number of 24 new escitalopram derivatives 
were modeled and their affinity to SERT were predicted in accordance with estimated 3D-
QSAR models. So, we chose to add a hydrophobic group (e.g. ethyl, i-propyl, propyl or 
t-butyl) to phenyl and also to the amine tail of escitalopram considering that the 
escitalopram derivatives antidepressant activity could be improved if the induced 
hydrophobic effect ensures an easier passage of the antidepressants through the 
biological membrane.  
At present, few SAR studies are rather confined to small data sets and are using both the 
classical quantitative structure-activity relationship (2D-QSAR) [13] and 3D-QSAR 
approaches [14–16], giving rise to enhanced knowledge about antidepressant drugs and 
their interactions with different membrane receptors. 
Results and Discussion 
3D-QSAR SERT antagonism activity model assessment of the sodium, H2O, OH-
phenyl and nitrogen amide ions contribution  
Initially, in the 3D-QSAR-ALMOND model, the individual atom probes sodium, OH-phenyl, 
nitrogen amide and water were used to predict the antidepressant biological activities, with 
a very poor correlation between experimental and in theory calculated binding affinities of 
antidepressants. Due to its negligible impact on the model, the above mentioned 
correlograms were removed from the initial set of probes. Thus, we considered necessary 
to supplement the reaction conditions with the presence of sodium, water, OH-phenyl and 
nitrogen amide ions in different combinations. It was noticed a clear improvement of 
statistic coefficients when combination of atom probes sodium and phenyl-OH, respective 
sodium and nitrogen amide atoms were used (Table 1).  
Tab. 1.   Summary of the ALMOND statistical parameters 
Statistical 
parameters 
Sodium and 
OH-phenyl 
atom probes  
Potassium 
and OH- 
phenyl atom 
probes 
Calcium 
and OH-
phenyl 
atom 
probes 
Sodium and 
nitrogen amide 
atom probes 
Calcium and 
nitrogen 
amide atom 
probes  
No. of 
molecules in 
training set 
15 15  15  15  15 
q
2 0.60  0.56  0.60  0.56 0.57 
r
2 0.80  0.81  0.80  0.82 0.82 
SDEP 0.69  0.72  0.70  0.72  0.72 
SDEC 0.47  0.46  0.48  0.45  0.46 
q
2 … cross-validated correlation coefficient; r
2-fitted correlation coefficient; SDEP- standard deviation of 
error prediction; SDEC- standard deviation of error calculation.  
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The observed and predicted biological activities of the SERT antagonists for the training 
and test sets and also the difference between them considering the presence of Na and 
OH-phenyl are presented below (Table 2). 
Tab. 2.   Observed and predicted affinities of antidepressants at SERT active site and 
difference between them (residual value) 
Antidepressant Predicted  affinities 
at SERT active site
Difference between 
observed and 
predicted affinities 
 
Observed 
affinities at 
SERT 
active site  Training set 
  A  B C A B C 
amitriptiline   8.46 8.94  8.77  8.95  −0.48  −0.31  −0.49 
atomoxetine   7.11 8.44  8.51  8.45  −1.33  −1.40  −1.34 
escitalopram   8.95  8.41  8.75  8.39   0.54  0.20  0.56 
fluoxetine   8.24  8.34  8.41  8.34  −0.10  −0.17  −0.10 
fluvoxamine   8.63  8.18  8.21  8.17   0.45  0.42  0.46 
imipramine   8.88 8.73  8.69  8.71   0.15  0.19  0.17 
milnacipram   6.82  7.84  7.86  7.84  −1.02  −1.04  −1.02 
mirtazepine   7.00  6.84  6.53  6.86   0.16  0.47  0.14 
nefazodone   7.16  6.68  6.33  6.64   0.48  0.83  0.52 
paroxetine 10.00 8.62  8.76  8.61   1.38  1.24  1.39 
reboxetine   6.35 6.51  7.18  6.48  −0.16  −0.83  −0.13 
sertraline   9.58  8.81  8.94  8.81   0.77  0.64  0.77 
trazodone   6.59  6.67  6.58  6.69  −0.08  0.01 −0.10 
venlafaxine   8.10  7.78  7.78  7.77   0.32  0.32  0.33 
zimelidine   7.18  8.08  8.11  8.07  −0.90  −0.93  −0.89 
   Test set 
desipramine 10.15  8.76  8.66  9.09   1.39  1.49  1.06 
nortryptiline   7.74 8.95  8.92  9.15  −1.21  −1.18  −1.41 
duloxetine   6.74 8.23  8.28  8.37  −1.49  −1.54  −1.63 
A sodium and OH-phenyl atom probes were used; 
B potassium and OH-phenyl atom 
probes were used; 
C calcium and OH-phenyl atom probes were used. 
 
Data shown in Table 2 is supported by the correlations between experimental and 
calculated biological antidepressant activities when Na and OH -phenyl atom probes were 
considered (Figure.1a; the test set is presented in triangles). In this case, the best 
predictions of antidepressant biological activity were obtained for trazodone (residual 
value=  −0.08) and fluoxetine (residual value=0.10) while PLS statistical results led to 
unsuitable correlations between predicted and observed biological activity for paroxetine 
(residual value = 1.38) and also for atomoxetine (residual value = −1.33). Also, the PLS 
regression resulted in a predictable satisfactory value of escitalopram SERT antagonism 
activity (residual value = 0.54).  
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Fig. 1.   Correlation between observed and predicted binding affinities of 
antidepressants at the active SERT site. (a) Sodium and OH-phenyl atom 
probes. (b) Potassium and OH-phenyl atom probes. (c) Calcium and OH-phenyl 
atom probes (The molecules in the the test set are presented in triangles) 238 S.  Avram  et al.:  
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3D-QSAR SERT antagonism activity model assessment of the potassium, H2O, OH-
phenyl and nitrogen amide ions contribution 
In a similar way with the previous 3D-QSAR models, a very poor correlation between 
observed and in predicted binding affinities of antidepressants were noticed when 
individual potassium, H2O and nitrogen amide atom probes were considered, but not when 
combination of potassium and OH-phenyl was used as grid atom probes (Table 1).  
Analyzing data, it can be noticed that the presence of the potassium ion only is not enough 
to induce an efficient antidepressant effect. By consequence, when the reaction conditions 
were enriched adding simultaneously potassium and OH-phenyl, a clear improvement of 
statistic coefficients was noticed (r
2 = 0.81, q
2 = 0.56). The observed and predicted bio-
logical activities of the SERT antagonists for the training and test sets and also the 
difference between them (K-OH phenyl atom probes were considered) are presented in 
Table 2. Correlations between the two affinities types are illustrated in Figure 1b. Results 
indicated a high accuracy in the SERT antagonism prediction when antidepressants like 
trazodone (residual value= 0.01), fluoxetine (residual value= 0.17) and also escitalopram 
(residual value= 0.20) are studied. Similar with previous results, the predicted biological 
activity of paroxetine and also of atomoxetine in correlation with the observed biological 
activities were poor. 
Chlorine is other important ion intervening in the electric signal transmission at the level of 
neuronal membrane. Thus, an objective of this study was to quantify the share of this ion 
in modulating the antidepressant effect of studied antidepressant molecules. As in the 
previous experiments, it was studied the effect of chlorine alone, or in association with 
other molecules (water, hydroxyl, amide nitrogen). PLS regression considering 3 latent 
variables (LV) resulted in a statistically unsatisfactory model (r
2 less than 0.7, and q
2 less 
than 0.50 respective) when (i) Cl-OH-phenyl, (ii) Cl-H2O and (iii) Cl-nitrogen amide were 
used in 3D-QSAR models. It was noticed that water, OH-phenyl and also nitrogen amide 
do not notably improve antidepressants’ activities. Due to its negligible impact on the 
model, 3D-QSAR models containing atom probes mentioned above have been removed 
from our study. 
3D-QSAR SERT antagonism model used calcium, water, OH-phenyl, nitrogen amide 
as atom probes. 
In this study it was assessed the effect of a bivalent cation, calcium, in inducing the 
antidepressant activity. The reaction conditions were similar to the previous: it was 
assessed the effect of calcium with or without water, hydroxyl and amide nitrogen. The 
suitable q
2 and r
2 values are presented in Table 1. The observed and predicted biological 
activities of the SERT antagonists and the difference between them using calcium-OH 
phenyl atom probes is presented in Table 2 and also the correlation between experimental 
and theoretical binding affinities of antidepressants at the active SERT site, when calcium 
ion and hydroxyl group are used as atom probes are presented in Figure 1c. 
The PLS regression led to a very good correlation between predicted and observed 
biological activities for fluoxetine (residual values = −0.1); trazodone (residual values= 
−0.1). In our intention to develop new escitalopram derivatives, we followed the correlation 
between predicted and observed biological actives of escitalopram. It is possible to notice 
that a residual value of 0.5 allowed us to predict the biological activity of escitalopram   3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive …  239 
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derivatives in respect with 3D-QSAR equation. The PLS statistic results proved that the 
presence of calcium and OH-phenyl have not improved the correlation between predicted 
and observed biological activity of paroxetine and atomoxetine. 
Tab. 3.   Predicted affinity of new escitalopram derivatives to SERT active site. The 
residual values (the biological activity for novel escitalopram derivatives 
differences to the parent biological activity) are in brackets. 
O
N
N
R
2
R
3
R
1
R
4
 
Substituents pKi
a  pKi
b  pKi
c  Escitalopram 
derivative  R
1 R
2 R
3 R
4      
Derivative 1  Cl  CH3 CH3 H  9.05(0.1)  9.02(0.07) 9.03(0.08) 
Derivative 2  Br  CH3 CH3 H  9.04(0.09)  9.01(0.06) 9.03(0.08) 
Derivative 3  OH  CH3 CH3 H  8.95(0)  8.96(0.01) 8.94(−0.01) 
Derivative 4  CH3 CH3 CH3 H  8.99(0.04)  8.98(0.03) 8.97(0.02) 
Derivative 5  NH-CH=O CH3 CH3 H  8.72(−0.23) 8.76(−0.19) 8.71(−0.24) 
Derivative 6  NO2  CH3 CH3 H  9.05(0.1)  9.04(0.09) 9.04(0.09) 
Derivative 7  OCH3 CH3 CH3 H  9.02(0.07)  9.06(0.11) 9.01(0.06) 
Derivative 8  F  CH3 CH3 F  9.09(0.14)  9.18(0.23) 9.08(0.13) 
Derivative 9  F  CH3 CH3 Cl  9.08(0.13)  9.14(0.19) 9.07(0.12) 
Derivative 10  F  CH3 CH3 allyl  8.94(−0.01) 8.95(0)  8.93(−0.02) 
Derivative 11  F  CH3 CH3 ethyl 9.16(0.21)  9.16(0.21) 9.15(0.2) 
Derivative 12  F  CH3 CH3  i-propyl 8.91(−0.04) 8.87(−0.08) 8.9(−0.05) 
Derivative 13  F  CH3 CH3 OCH3  9.12(0.17)  9.17(0.22) 9.11(0.16) 
Derivative 14  F  CH3 CH3  t-butyl 9.06(0.11)  9.04(0.09) 9.05(0.1) 
Derivative 15  F  CH3 CH3 OH  8.95(0)  9.03(0.08) 8.94(−0.01) 
Derivative 16  F  H  H  H  8.75(−0.2) 8.68(−0.27) 8.73(−0.22) 
Derivative 17  F  H  CH3 H  8.99(0.04)  8.94(−0.01) 8.98(0.03) 
Derivative 18  F  allyl  CH3 H  8.89(−0.06) 8.86(−0.09) 8.88(−0.07) 
Derivative 19  F  i-propyl CH3 H  8.98(0.03)  8.94(−0.01) 8.96(0.01) 
Derivative 20  F  ethyl  ethyl  H  9.38(0.43) 9.35(0.4) 9.37(0.42) 
Derivative 21  F  propyl  propyl  H  9.36(0.41) 9.28(0.33) 9.34(0.39) 
Derivative 22  F  t-butyl  t-butyl H  9.23(0.28)  9.14(0.19) 9.22(0.27) 
Derivative23 F  ethyl  ethyl F  9.43(0.48) 9.45(0.5) 9.41(0.46) 
Derivative24 F  t-butyl  t-butyl F  9.32(0.37)  9.31(0.36) 9.31(0.36) 
a Na-OH-phenyl atom probes; 
b K-OH-phenyl atom probes; 
c Ca-OH-phenyl atom probes. 
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Novel structures of escitalopram derivatives with possible antidepressant profile 
Nowadays, the major problem of antidepressants’ utilization is governed by severe side-
effects which were already mentioned above, especially suicidal behavior and related 
thoughts induction, excepting the SSRI escitalopram. It has been discovered that in severe 
depressions, escitalopram has the advantage to have a more rapid action (depressive 
symptoms diminish after 1–2 weeks instead of 3–4 weeks) and less side effects compared 
to other SSRIs. Moreover, a meta-analysis of clinical trials database conducted by the 
escitalopram manufacturer Lundbeck found no indication that escitalopram would provoke 
suicidal behavior compared with placebo in patients with major depressive disorder and 
anxiety disorders, on the contrary, suicidal thoughts in the escitalopram group were 
significantly decreased. Due to aforementioned high importance of escitalopram, we have 
finally used a set of 24 potential new escitalopram derivatives and calculated their 
theoretical binding constants by using our above presented 3D-QSAR equations (Table 3).  
The reliably predicted antidepressants’ activity at the SERT allows us to design new 
escitalopram derivatives which could be used as potential antidepressants. In our opinion 
an important improvement of the SERT antagonism activity should be obtained by 
facilitating the escitalopram membrane crossing as well as by generating more negative 
electrostatic contacts at the active site of the SERT. So, we enhanced the number of 
hydrophobic contacts of escitalopram, by adding allyl, ethyl, i-propyl, propyl, and t-butyl 
substituents as well as the number of hydrophilic contacts by adding halogen (F, Cl, Br), 
hydroxyl, nitro, methoxy or amide substituents.  
The calculated values are suggesting a real improvement of escitalopram’s activity within 
the SERT for derivative 20 (R
1=F, R
2= ethyl, R
3= ethyl, R
4=H), derivative 21 (R
1=F, R
2= 
propyl, R
3= propyl, R
4=H) and derivative 23 (R
1=F, R
2= ethyl, R
3= ethyl, R
4=F) (Table 3). 
There is no improvement for the escitalopram derivative 5 (R
1= NH-CH=O, R
2=CH3, R
3= 
CH3, R
4=H), derivative 16 (R
1=F, R
2=H, R
3=H, R
4=H) (Table 3) in interaction with SERT 
receptor. All these observations sustained the idea that the simultaneous presence of 
diethyl groups at the amine tail and difluoro atoms at the phenyl ring increased the 
antidepressant activity. On the other hand, it could be noticed that the drastically decrease 
of antidepressant activity is induced by the presence of dimethyl or dibutyl group linked by 
the amine tail or by the presence of primary amine. Same effect was recorded when the F, 
Cl- substituted phenyl or F, Br- substituted phenyl are considered.  
Experimental 
Data set 
The binding constants of 18 antidepressant active compounds, with regard to serotonin 
transporter, were compiled from literature: (i) serotonin-reuptake inhibitors: zimelidine [17], 
fluoxetine [18], paroxetine [19], sertraline [18], fluvoxamine [18], escitalopram [18]; (ii) 
selective norepinephrine-reuptake inhibitors: reboxetine [20] and atomoxetine [20]; (iii) 
nonselective norepinephrine-reuptake inhibitors: desipramine [20], nortryptiline [17]; (iv) 
dual-action reuptake inhibitors: amitriptyline [21], imipramine [22], and the newer in the 
class – venlafaxine [21], milnacipran [21], duloxetine [21]; (v) new agents with complex 
mechanism of action like mirtazapine[23], nefazodone [24] and trazodone [22]. The list of 
studied compounds, and also their 2D – structures are shown in Table 4. Even if the   3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive …  241 
Sci Pharm. 2010; 78 233–248. 
number of compounds included in this study is not large, the data set was selected due to 
following criteria: (i) a large range of observed biological activities (6.35<pKi<10.15); (ii) 
favorable pharmacokinetic and pharmacodinamic properties covering the interactions with 
SERT compiled from literature [17–24]; (iii) the variety of substituents, covering as many 
as possible chemical classes of compounds. 
Tab. 4.   The chemical structures and observed biological activity of antidepressant 
agents at the SERT site pKiSERT  
Antidepressant 2D-STRUCTURE  pKi SERT 
serotonin-reuptake inhibitors 
zimelidine  
N
N
Br
H
 
7.18 [17] 
fluoxetine 
O
F
F
F
N H
 
8.24 [18] 
paroxetine 
O
O
N
H
O
F  
10 [19] 
sertraline 
N H
Cl
Cl  
9.58 [18] 
fluvoxamine 
N
F F
F
O
NH2
O
 
8.63 [18] 
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Tab. 4.   (Cont.) 
Antidepressant 2D-STRUCTURE  pKi SERT 
serotonin-reuptake inhibitors 
escitalopram 
O
N
N
F
 
8.95 [18] 
selective norepinephrine-reuptake inhibitors 
reboxetine 
NH
O O
O
H
 
6.35 [20] 
atomoxetine 
ON
H
 
7.11 [20] 
nonselective norepinephrine-reuptake inhibitors 
desipramine  
N
N H
 
6.74 [20] 
nortryptiline 
N
H  
7.74 [17] 
dual-action reuptake inhibitors 
amitriptyline 
N
 
8.46 [21] 
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Tab. 4.   (Cont.) 
Antidepressant 2D-STRUCTURE  pKi SERT 
dual-action reuptake inhibitors 
imipramine 
N
N
 
8.88 [22] 
venlafaxine 
N
O
OH  
8.10 [21] 
milnacipran  N H2
N
O  
8.07 [21] 
duloxetine 
O
S
N
H
 
10.15 [21] 
new agents with complex mechanism of action 
mirtazapine  N
N
N
 
7.00 [23] 
nefazodone 
N
N
N
O
O
N
N
Cl  
7.16 [24] 
trazodone 
NN
N
Cl
N
N
O
 
6.59 [22] 
The references used for observed biological activity of antidepressants are presented in 
brackets. 244 S.  Avram  et al.:  
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Molecular modeling and minimum energy of antidepressants  
Three dimensional structures of studied compounds were obtained using the Sybyl 7 
software. Further, in our study, energy minimized conformations of antidepressants were 
primarily established using the Maxim 2 minimization routine in Sybyl 7 [25] with Tripos 
force field, Conjugate-Gradient algorithm. After having obtained the appropriate 
conformations, the Gasteiger-Marsili partial charges of the compounds were loaded on the 
chemical structures from the Sybyl 7 dictionary.  
ALMOND strategy 
These data were introduced into ALMOND [26] incorporated into Sybyl 7.3, where the 
calculation of the descriptors was performed. In our 3D-QSAR study default probes: 
sodium, potassium, chlorine and calcium (used as biological membrane ionic 
environment), water (used as electrostatic field), OH-phenyl (used as hydrogen bond 
donor) and nitrogen amide (used as hydrogen bond acceptor) were used in succession or 
in different combinations like (Na- H2O, Na-OH-phenyl, Na-N1 amide; K- H2O, K-OH-
phenyl, K-N1 amide; Cl- H2O, Cl-OH-phenyl, Cl-N1 amide; Ca- H2O, Ca-OH-phenyl, Ca-N 
amide). Not all these combinations of atom probes were considered in the final models. 
Most of the Almond parameters were set to default values, for example, the grid spacing 
was equal to 0.5 A˚, the smoothing window of the correlograms was set to 0.8, and the 
size of the correlograms was automatically established by the program. 
Chemometric analyses 
The regression analysis was performed using the Partial Least Squares (PLS) [27, 28] 
algorithm within Sybyl 7. The optimum number of PLS components (latent variables, LV) 
was chosen by kept changes in the predictivity index (q
2) model evaluated by applying the 
cross-validation procedure available in ALMOND. Also, SDEP (standard deviation of error 
prediction) [25] and SDEC (standard deviation of error calculation) [25] were evaluated. 
Further, the control criterions: r
2 coefficient [25] was calculated in Sybyl ALMOND module 
by non-cross-validated method [27, 28].  
Training and testing sets 
Interpretable models need to be constructed using a minimum set of compounds offering 
an enough large window of activities. For this reason we created two sets in which 15 
molecules (6.35<pKi<10.15) were used as training set and 3 molecules were used for 
testing. The composition of both sets was kept unchanged during the study as follows: 
training set comprised amitriptiline, atomoxetine, escitalopram, fluoxetine, fluvoxamine, 
imipramine, milnacipram, mirtazepine, nefazodone, paroxetine, reboxetine, sertraline, 
trazodone, venlafaxine, zimelidine while desipramine, nortryptiline and duloxetine 
belonged to the test set. 
Modeling new escitalopram derivatives with potential affinity to SERT 
Due to the before mentioned high importance of escitalopram as antidepressant agent, a 
set of 24 new escitalopram derivatives was created in order to predict their antagonism 
activity to SERT using our above presented 3D-QSAR models. In this respect, we followed 
two strategies: first, we generated more negative electrostatic contacts by adding halogen 
(F, Cl, Br), hydroxyl, nitro, methoxy or amide substituents at R1, respective R4 positions 
(see Table 3) of and, secondly, we enhanced the number of hydrophobic contacts of   3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive …  245 
Sci Pharm. 2010; 78 233–248. 
escitalopram, by adding allyl, ethyl, i-propyl, propyl, and t-butyl substituents at R
2–R
4 
positions (see Table 3). The strategy of molecular modeling and minimum energy of 
escitalopram derivatives were performed in Sybyl 7.3 in the similar manner presented 
in 3.2. 
Conclusions 
ALMOND-based 3D-QSAR models can give different kind of information like reliable 
prediction of the biological activity of compounds belonging to the data set and chemical 
interpretation of the obtained results. In this paper we have reported alignment- 
independent 3-D QSAR studies on a series of 18 antidepressants already accepted in the 
clinical treatment and also of new 24 escitalopram derivatives against SERT transporter 
into QSAR models. In our study, 3D-QSAR-ALMOND models were used to elucidate the 
most important physicochemical properties which are responsible for the binding 
properties of 18 antidepressant agents at SERT active site. An analysis of our QSAR 
results on antidepressants interactions with serotonin transporter (SERT) brings up a 
number of points of interest. In our study, seven atom probes (biological membrane ions 
(sodium, chlorine, potassium, and calcium), water (as electrostatic field), nitrogen amide 
(as hydrogen-bond donor) and OH-phenyl (used as hydrogen bond acceptor) were 
considered. The PLS significant statistic results were obtained when ions atom probes 
were considered in combination with OH –phenyl and N1 amide. 
Comparing the PLS statistic results it was possible to put in evidence some similarities and 
differences between the models. The influences of these descriptors to binding affinities 
could be laid down in five QSAR equations which show that the binding affinity of an 
antidepressant can be influenced by the simultaneous presence of the cations and of the 
hydroxyl anion, while the simultaneous presence of water atoms and of the cations can 
influence the binding affinity, but certainly in a weaker manner than the presence of 
hydroxyl.  
Our results indicate that the judicious modulation of the physicochemical properties, 
particularly hydrophobic and electronic ones, may be very useful in designing new 
antidepressant drugs. Considering the above set of 24 new potential escitalopram 
structures, the established equations could be possibly used as a guidance to enhance or 
diminish Ki values according to the particular biological need. In our opinion, these 
compounds represented a suggestion for further clinical and also, molecular simulation 
studies. 
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